skip navigation
A B C D E F G H I J K L M N O P Q

Test Identifier Information

 
Registration CodeCTGN
Method

Fluorescence in situ hybridisation (FISH) on formalin fixed paraffin embedded (FFPE) tissue slides using a breakapart probe specific for the ROS1 rearrangement.

Diagnostic Use / Indications

ROS1 rearrangements are potent oncogenic drivers in lung cancer. While identified in <2% of NSCLC, tumours positive for ROS1 rearrangements can be targeted by specific TKIs.

It has been determined that ROS1 rearrangements are not present alongside other oncogenic driver mutations, such as EGFR and ALK, therefore sequential testing is recommended.

External Price$511.01(Exclusive of GST)
  

Specimen Collection

 
Pre-Testing Requirements

Please call the laboratory in advance if there is particular urgency for a result.

Specimen Collection Protocols

·   Only tissue preserved in neutral buffered formalin and paraffin embedded is suitable for use. NB: Samples de-calcified in Formic acid are not suitable for FISH as this process affects the integrity of the DNA.

·   Tissue specimens should be cut into sections of 2-4µm, ideally on poly-L-lysine slides.

·   Ensure one H&E slide and 2-3 unprocessed slides are supplied.

·   Slide must be clearly labelled with two patient identifiers, matching those on the request form.

The H&E slide must be assessed by a pathologist prior to receipt, and appropriate areas for analysis should be clearly marked.

Patient SpecimenParaffin embedded tumour section slides
Sample Delivery to LabIn slide-holders or boxes at room temperature.
  

CHLabs Laboratory

 
DepartmentHaematology - Cytogenetics
Contact Details Email Email
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Contact Phone Number03 3786 007 ext 86007
Test AvailabilityMon-Fri, 8am-5pm. Samples are processed 3 times per week, during business hours. Urgent testing by arrangement
Turnaround TimeUrgent 1-3 days. Routine 5 days
Interpretation

ROS1 rearrangement is reported if more than 15% of cells examined show a signal pattern consistent with a clinically significant ROS1 rearrangement.

 

Rearrangements and copy number changes which have no proven clinical impact may also be detected using this probe. These will not be reported.

 

 

 

 

 

 

 


CHL Follow us on Facebook